Diverse structures and antihepatoma effect of sesquiterpenoid dimers from Artemisia eriopoda by AKT/STAT signaling pathway  

作　　者：Xiaofeng He Wenjing Ma Jing Hu Tianze Li Changan Geng Yunbao Ma Mengfei Wang Kexin Yang Xuemei Zhang Ji-Jun Chen 

机构地区：[1]State Key Laboratory of Phytochemistry and Plant Resources in West China,Kunming Institute of Botany,Chinese Academy of Sciences,Kunming 650201,PR China [2]University of Chinese Academy of Sciences,Beijing 100049,PR China

出　　处：《Signal Transduction and Targeted Therapy》2023年第3期898-900,共3页信号转导与靶向治疗（英文）

基　　金：This work was financially supported by the Key Program of the National Natural Science Foundation of China(22137008);the Xingdian Yingcai Project(YNWR-KJLJ-2019-002);the Youth Fund Program of the National Natural Science Foundation of China(82104040);the Funded by CAS Special Research Assistant(E12D9211Q1);the Youth Innovation Promotion Association,CAS(2020386);the Reserve Talents of Young and Middle-aged Academic and Technical Leaders in Yunnan Province(202105AC160021);Postdoctoral Directional Training Foundation of Yunnan Province(E131821261).The authors are grateful to Prof.Jian Ding,Prof.Hongchun Liu,and Dr.Hui Xu(Shanghai Institute of Materia Medica,Chinese Academy of Sciences)for their kind help in cytotoxic assay against THLE-2 cells,to Ms.Yaomei He and Senior Engineer Lian Yang(Kunming Institute of Botany,Chinese Academy of Sciences)for their help in network pharmacology analysis and the isothermal titration calorimetry and Surface Plasmon Resonance assay.

摘　　要：Dear Editor,Liver cancer as a common malignant tumor has become a major source of morbidity and mortality worldwide.1 Currently,four synthetic drugs and three monoclonal antibody drugs have been approved for the treatment of hepatocellular carcinoma(HCC)since 2007.Whereas,the disadvantages of the above drugs such as low response rates,severe side effects,and drug resistance hamper their therapeutic effects.Structurally and biologically diverse natural products are a major source in the search for novel antihepatoma agents.

关 键 词：DRUGS mortality Liver 

分 类 号：R735.7[医药卫生—肿瘤]